In a groundbreaking move, the U.S. FDA announced a revolutionary initiative on April 10, 2025, to phase out animal testing in drug development, marking a significant shift towards human-relevant, science-driven alternatives. This initiative represents a pivotal moment in the industry, formalizing the agency’s commitment to incorporating New Approach Methodologies (NAMs) into regulatory review processes.
Concurrently, the National Institutes of Health (NIH) unveiled a new internal office to prioritize human-based research and announced the cessation of funding for animal-only studies. These strategic shifts not only impact scientific workflows but also reshape the intellectual property landscape, presenting both risks and opportunities for innovators in the biotech sector. The move towards human-relevant technologies as the foundation for safety and efficacy claims underscores the importance of patenting platforms, data models, and trial designs that align with evolving regulatory standards.
Read more from jdsupra.com